Becton Dickinson and Co vs Iris Energy Limited — how do they compare? Becton Dickinson and Co trades at $154.99 (market cap $41.51B), while Iris Energy Limited trades at $38.27 (market cap $13.80B). The key difference: Becton Dickinson and Co is far larger — about 3× Iris Energy Limited's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals.
| BDX | IREN | |
|---|---|---|
Market Cap | $41.51B | $13.80B |
Sector | Health | Energy |
52-Week High | $185.39 | $76.41 |
52-Week Low | $135.49 | $15.40 |
Enterprise Value | $57.97B | $15.55B |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
IREN trades at $38.98, down 5.18% on the day, amid a bearish technical signal and recent earnings misses. The company is transitioning from Bitcoin mining to AI infrastructure, showing strong revenue growth projections for 2026 ($757M) and a net income margin improvement to 20.87%. However, negative ROE and ROA highlight profitability challenges. Analyst consensus remains bullish with a $79.11 price target, but high valuation ratios (P/E 50.14, P/S 14.99) suggest premium pricing.
The outlook hinges on successful execution of AI cloud expansion, with key risks including competitive pressures from Meta's cloud ambitions and operational scalability. Investors face a high-risk, high-reward scenario, balancing analyst optimism against technical weakness and recent stock volatility. Near-term catalysts include potential contracts and capacity milestones, but misses on earnings expectations warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →